Active substance
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| Amelivu | 10 mg/ml | Solution for injection · Intravitreal use | 1 Vial | SAR 1530.65 | Biological · Prescription | Samsung Bioepis Co Ltd | Valid |
| LUCENTIS 10MG-ML INTRAVITREAL Injection | 10 mg/ml | Solution for injection · Intravenous use | 1 Vial | SAR 2353.90 | Biological · Prescription | NOVARTIS PHARMA AG | Valid |
| Ravegza 2.3 mg per 0.23 ml | 10 mg/ml | Solution for injection · Intravitreal use | 1 Vial | SAR 2206.80 | Biological · Prescription | MS Pharma Saudi (MSPS) | Valid |
| ximluci | 10 mg/ml | Solution for injection · Intravitreal use | 1 Vial | SAR 1618.30 | Biological · Prescription | STADA ARZNEIMITTEL GmbH | Valid |
AGE RELATED MACULAR DEGENERATION; DIABETIC RETINOPATHY
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| LUCENTIS | 10MG/ML; 6MG/ML | injectable · injection | GENENTECH | Prescription | 30 Jun 2006 |
| BYOOVIZ | 0.5MG(10MG/ML) | injectable · injection | SAMSUNG BIOEPIS CO LTD | Prescription | 17 Sep 2021 |
| SUSVIMO | 100MG/ML | solution · injection | GENENTECH INC | Prescription | 22 Oct 2021 |
| CIMERLI | 0.3MG(6MG/ML); 0.5MG(10MG/ML) | injectable · injection | SANDOZ INC | Prescription | 2 Aug 2022 |
| NUFYMCO | 6MG/ML; 10MG/ML | injection | FORMYCON AG | Prescription | 18 Dec 2025 |
| RANLUSPEC | 10MG/ML; 6MG/ML | injection | LUPIN LIMITED | Prescription | 2 Jun 2026 |
Lucentis is indicated in adults for: The treatment of neovascular (wet) age-related macular degeneration (AMD) The treatment of visual impairment due to choroidal neovascularisation (CNV) The treatment of visual impairment due to diabetic macular oedema (DME) The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)
Byooviz is indicated in adults for: The treatment of neovascular (wet) age-related macular degeneration (AMD) The treatment of visual impairment due to diabetic macular oedema (DME) The treatment of proliferative diabetic retinopathy (PDR) The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) The treatment of visual impairment due to choroidal neovascularisation (CNV)
Ranivisio is indicated in adults for: • The treatment of neovascular (wet) age-related macular degeneration (AMD) • The treatment of visual impairment due to diabetic macular oedema (DME) • The treatment of proliferative diabetic retinopathy (PDR) • The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) • The treatment of visual impairment due to choroidal neovascularisation (CNV)
Ximluci is indicated in adults for: The treatment of neovascular (wet) age-related macular degeneration (AMD) The treatment of visual impairment due to diabetic macular oedema (DME) The treatment of proliferative diabetic retinopathy (PDR) The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) The treatment of visual impairment due to choroidal neovascularisation (CNV)
Rimmyrah is indicated in adults for: The treatment of neovascular (wet) age-related macular degeneration (AMD) The treatment of visual impairment due to diabetic macular oedema (DME) The treatment of proliferative diabetic retinopathy (PDR) The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) The treatment of visual impairment due to choroidal neovascularisation (CNV)
Treatment of neovascular (wet) age-related macular degeneration (AMD), visual impairment due to diabetic macular oedema (DME), proliferative diabetic retinopathy (PDR), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) and visual impairment due to choroidal neovascularisation (CNV).
Ranluspec is indicated in adults for: The treatment of neovascular (wet) age-related macular degeneration (AMD) The treatment of visual impairment due to diabetic macular oedema (DME) The treatment of proliferative diabetic retinopathy (PDR) The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) The treatment of visual impairment due to choroidal neovascularisation (CNV)
Rexatilux is indicated in adults for: - The treatment of neovascular (wet) age-related macular degeneration (AMD) - The treatment of visual impairment due to diabetic macular oedema (DME) - The treatment of proliferative diabetic retinopathy (PDR) - The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) - The treatment of visual impairment due to choroidal neovascularisation (CNV).
Vislyfa is indicated in adults for: The treatment of neovascular (wet) age-related macular degeneration (AMD) The treatment of visual impairment due to diabetic macular oedema (DME) The treatment of proliferative diabetic retinopathy (PDR) The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) The treatment of visual impairment due to choroidal neovascularisation (CNV)
Susvimo is indicated in adult patients for the treatment of neovascular (wet) age-related macular degeneration (nAMD) who have achieved stable disease after previously responding to intravitreal treatment with a vascular endothelial growth factor (VEGF) inhibitor medicinal product.
Treatment of neovascular age-related macular degeneration in adults.
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| LUCENTIS | 02296810 | 10 MG / ML | SOLUTION · INTRAVITREAL | NOVARTIS PHARMACEUTICALS CANADA INC |
| LUCENTIS | 02425629 | 10 MG / ML | SOLUTION · INTRAVITREAL | NOVARTIS PHARMACEUTICALS CANADA INC |
| MELVIZO | 02525852 | 10 MG / ML | SOLUTION · INTRAVITREAL | SAMSUNG BIOEPIS CO., LTD |
| RANOPTO | 02542250 | 10 MG / ML | SOLUTION · INTRAVITREAL | TEVA CANADA LIMITED |
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.